Arrowhead Research Corporation
ARWR Real Time Price USDRecent trades of ARWR by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Daniel S. Goldman House / D | Sale $1,001 - $15,000 | Jan 31, 2023 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ARWR holdings by institutional investors
Quarterly net insider trading by ARWR's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
ARWR Estimated quarterly lobbying spending
ARWR Revenue by Segment or Geography
New ARWR patent grants
-
Patent Title: Rnai agents for inhibiting expression of activin receptor-like kinase 7 (alk7), compositions thereof, and methods of use Oct. 14, 2025
-
Patent Title: 5′-cyclo-phosphonate modified nucleotides Oct. 14, 2025
-
Patent Title: Rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions thereof, and methods of use Aug. 05, 2025
-
Patent Title: Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) Jul. 22, 2025
-
Patent Title: Rnai agents for inhibiting expression of mucin 5ac (muc5ac), compositions thereof, and methods of use Jul. 22, 2025
-
Patent Title: Rnai agents for inhibiting expression of hif-2 alpha ( Feb. 11, 2025
-
Patent Title: Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin Jan. 07, 2025
-
Patent Title: Alpha-v beta-6 integrin ligands and uses thereof Dec. 24, 2024
-
Patent Title: Targeting ligands for therapeutic compounds Oct. 15, 2024
-
Patent Title: Rnai agents for inhibiting expression of complement component c3 (c3), pharmaceutical compositions thereof, and methods of use Oct. 08, 2024
-
Patent Title: Organic compositions to treat hsf1-related diseases Sep. 17, 2024
-
Patent Title: Trialkyne linking agents and methods of use Aug. 20, 2024
-
Patent Title: Rnai agents for inhibiting expression of pnpla3, pharmaceutical compositions thereof, and methods of use Aug. 06, 2024
-
Patent Title: Compositions and methods for inhibiting expression of rrm2 genes Mar. 05, 2024
-
Patent Title: Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use Feb. 27, 2024
-
Patent Title: Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use Jan. 30, 2024
-
Patent Title: Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use Dec. 19, 2023
-
Patent Title: Compositions and methods for inhibiting gene expression of hif2alpha Dec. 12, 2023
-
Patent Title: Rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use Apr. 18, 2023
-
Patent Title: Integrin ligands and uses thereof Mar. 07, 2023
-
Patent Title: Rnai agents for hepatitis b virus infection Feb. 28, 2023
-
Patent Title: Compositions and methods for inhibiting gene expression of hepatitis b virus Dec. 08, 2020
-
Patent Title: Compositions and methods for inhibiting gene expression of hif2alpha May. 22, 2018
-
Patent Title: Compositions and methods for inhibiting expression of rrm2 genes Apr. 10, 2018
-
Patent Title: Compositions and methods for inhibiting gene expression of lpa Apr. 03, 2018
-
Patent Title: Interfering rna delivery system and uses thereof Apr. 03, 2018
-
Patent Title: Rnai inhibition of alpha-enac expression Mar. 13, 2018
-
Patent Title: Organic compositions to treat epas1-related diseases Jan. 16, 2018
-
Patent Title: Compositions and methods for inhibiting gene expression of factor xii Oct. 31, 2017
-
Patent Title: Disulfide-containing alkyne linking agents Oct. 31, 2017
-
Patent Title: Galactose cluster-pharmacokinetic modulator targeting moiety for sirna Oct. 24, 2017
-
Patent Title: Interfering rna delivery system and uses thereof Oct. 24, 2017
-
Patent Title: Rnai-mediated inhibition of phosphodiesterase type 4 for treatment of camp-related ocular disorders Sep. 19, 2017
-
Patent Title: Organic compositions to treat beta-enac-related diseases Sep. 05, 2017
-
Patent Title: Rnai-mediated inhibition of connexin 43 for treatment of iop-related conditions Sep. 05, 2017
-
Patent Title: Rnai-mediated inhibition of histamine receptor h1-related conditions Aug. 29, 2017
-
Patent Title: Transferrin/transferrin receptor-mediated sirna delivery Feb. 07, 2017
-
Patent Title: Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma Jan. 24, 2017
-
Patent Title: Organic compositions to treat hsf1-related diseases Jan. 10, 2017
-
Patent Title: Low density lipoprotein receptor-mediated sirna delivery Dec. 27, 2016
-
Patent Title: Peptide-based in vivo sirna delivery system Dec. 27, 2016
-
Patent Title: Polyconjugates for delivery of rnai triggers to tumor cells in vivo Nov. 08, 2016
-
Patent Title: Rnai inhibition of alpha-enac expression Oct. 25, 2016
-
Patent Title: Rnai-mediated inhibition of connexin 43 for treatment of iop-related conditions Oct. 25, 2016
-
Patent Title: Poly(vinyl ester) polymers for in vivo nucleic acid delivery Oct. 25, 2016
-
Patent Title: Rnai-mediated inhibition of phosphodiesterase type 4 for treatment of camp-related ocular disorders Sep. 27, 2016
-
Patent Title: Poly(acrylate) polymers for in vivo nucleic acid delivery Sep. 27, 2016
-
Patent Title: Rnai-mediated inhibition of tumor necrosis factor α-related conditions Sep. 20, 2016
-
Patent Title: Rnai-related inhibition of tnf-alpha signaling pathway for treatment of ocular angiogenesis Aug. 23, 2016
-
Patent Title: Organic compositions to treat beta-enac-related diseases Jun. 28, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ARWR from public contracts
Recent insights relating to ARWR
Recent picks made for ARWR stock on CNBC
ETFs with the largest estimated holdings in ARWR
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ARWR stock a Buy, Sell, or Hold?
- What is the price target for $ARWR stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ARWR stock?
- Who owns the most shares of $ARWR stock?
- What funds own $ARWR stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ARWR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
- Address Pasadena, CA
- Market Cap 5.6 billion
- Employees 609
- Industrial Classification Pharmaceutical Preparations